+
GIP Agonist
Dual Mechanism
Tirzepatide For Sale — Research-Grade Dual Agonist
Tirzepatide is the most advanced dual GLP-1/GIP receptor agonist in metabolic research — producing greater weight reduction than any single-receptor GLP-1 agonist in clinical trials. Independently tested to ≥99% purity. Lyophilized powder and nasal spray available. Free shipping over $100.
Third-Party COA
Dual GLP-1 + GIP
USA Manufactured
Free Shipping $100+
Ships Same Day
Research Compound Overview
What Is Tirzepatide? The World’s Most Potent Weight Loss Research Peptide
Tirzepatide is a synthetic 39-amino acid peptide developed by Eli Lilly that acts as a dual agonist at both the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual-receptor mechanism is what separates tirzepatide from all single-receptor GLP-1 agonists like semaglutide and liraglutide — producing superior metabolic effects in both preclinical and clinical research settings.
PureRawz offers tirzepatide for sale strictly as a research peptide for in vitro and preclinical laboratory use. Every batch is independently verified to ≥99% purity via HPLC and Mass Spectrometry by MZ Biolabs, with a batch-specific Certificate of Analysis published publicly on every product page.
PureRawz tirzepatide is sold exclusively for laboratory research purposes. It is not pharmaceutical-grade Mounjaro or Zepbound — those are FDA-approved prescription products by Eli Lilly manufactured under pharmaceutical GMP standards. It is not compounded tirzepatide and is not intended for human injection or weight loss use. For medical purposes, consult a licensed physician.
Tirzepatide Product Specifications
| Compound Name | Tirzepatide (LY3298176) |
| Class | Dual GLP-1 / GIP Receptor Agonist (Twincretin) |
| Amino Acids | 39 |
| Molecular Formula | C₂₂₅H₃₄₈N₄₈O₆₈ |
| Molecular Weight | 4813.48 g/mol |
| CAS Number | 2023788-19-2 |
| GLP-1 Homology | ~39% with native GLP-1 |
| Purity (PureRawz) | ≥99% HPLC verified |
| Testing Lab | MZ Biolabs (independent, third-party) |
| Half-Life | ~5 days |
| Available Forms | Lyophilized Powder · Nasal Spray |
| Intended Use | Research purposes only — not for human use |
Dual Mechanism of Action
How Tirzepatide Works — Two Receptors, One Peptide
Tirzepatide’s superior clinical outcomes are explained by its simultaneous activation of two distinct metabolic receptor pathways. Understanding both is essential for designing accurate preclinical research protocols.
- Glucose-dependent insulin secretion from pancreatic beta cells
- Glucagon suppression — reduces hepatic glucose output
- Hypothalamic satiety signaling — reduces appetite and food intake
- Slows gastric emptying — prolongs postprandial satiety
- Cardiovascular protective effects via GLP-1R in heart tissue
- Amplifies insulin secretion — additive effect on top of GLP-1
- Promotes adipocyte lipolysis — fat cell breakdown in adipose tissue
- May improve insulin sensitivity in peripheral tissues
- Bone protective effects via GIP receptors in osteoblasts
- Potential neuroprotective effects via GIP receptors in the brain
Why dual agonism produces superior outcomes: GLP-1 alone reduces appetite and improves glycemia. GIP adds adipocyte lipolysis and amplified insulin response. Together, they address metabolic dysfunction via independent but synergistic pathways — which is why tirzepatide outperforms single-receptor GLP-1 agonists like semaglutide in head-to-head clinical data. This is the core research value of tirzepatide as a distinct compound.
Available Formats
Tirzepatide For Sale in Multiple Research Forms
PureRawz offers research-grade tirzepatide in two delivery formats. Both use the same ≥99% purity compound with batch-specific third-party COA documentation.
Freeze-dried tirzepatide in sealed glass vials. Reconstitute with bacteriostatic water. Stable 24+ months at −20°C. The standard format for subcutaneous preclinical research protocols requiring precise weekly dosing. Available in 2mg, 5mg, 10mg, and bulk 20mg vials for extended research programs.
Research-grade tirzepatide in intranasal delivery format. Designed for protocols examining mucosal GLP-1/GIP receptor engagement and systemic bioavailability via the nasal route. No reconstitution required — consistent, precise dosing per spray actuation.
Head-to-Head Comparison
Tirzepatide vs Semaglutide vs Liraglutide — The Research Data
Tirzepatide vs semaglutide is the most debated comparison in metabolic research in 2026. The SURMOUNT-5 trial settled the efficacy question head-to-head. Here’s how all three compounds compare across key research parameters.
| Factor | Tirzepatide | Semaglutide | Liraglutide |
|---|---|---|---|
| Receptor Target | GLP-1 + GIP (dual) | GLP-1 only | GLP-1 only |
| Half-Life | ~5 days | ~7 days | ~13 hours |
| Dosing Frequency | Once weekly | Once weekly | Once daily |
| Weight Reduction (clinical) | ~22% body weight | ~15–17% | ~5–8% |
| Glycemic Control | Superior (SURPASS vs SUSTAIN) | Strong | Moderate |
| Head-to-Head Data | SURMOUNT-5 (2024) | Comparator arm | No direct trial |
| Cardiovascular Data | SURMOUNT-MMO (ongoing) | SELECT trial (2023) | LEADER trial |
| Adipose Tissue Research | GIP adds lipolysis | GLP-1 only | GLP-1 only |
| PureRawz Price | From $54.99 | From $49.99 | From $39.99 |
All products sold as research compounds only. Not for human use. Clinical data referenced from published peer-reviewed sources.
Why PureRawz
Why Researchers Buy Tirzepatide From PureRawz
Tirzepatide’s complexity — a 39-amino acid modified peptide with a C18 fatty diacid chain — makes purity verification more technically demanding than most research peptides. PureRawz holds three non-negotiable standards.
Every tirzepatide batch is tested by MZ Biolabs — accredited, independent, third-party. The COA is published publicly on every product page, searchable by lot number. For complex modified peptides, Mass Spectrometry sequence confirmation is included in every COA.
HPLC and Mass Spectrometry confirm both purity and molecular identity on every batch. Tirzepatide contains a fatty acid modification critical to its half-life — impurities or truncated sequences would fundamentally alter research outcomes. Full impurity profiles are documented.
Manufactured and fulfilled from a US facility. Orders before 2PM EST ship same business day. All peptide orders are cold-packed where required. Domestic delivery in 2–4 business days. Discreet, unmarked packaging on every order.
Research Overview
Tirzepatide Research: Beyond the Weight Loss Headlines
Tirzepatide’s research profile extends well beyond the weight management data that dominates public discussion. Its dual GLP-1/GIP mechanism opens unique research directions not available with single-receptor agonists. The following covers research context only. Tirzepatide is not recommended for self-administration.
Primary Research Areas
-
Obesity & Body Weight (SURMOUNT Program): The SURMOUNT clinical trial program established tirzepatide’s ~22% body weight reduction — the largest weight reduction ever documented for any pharmaceutical in obesity trials. SURMOUNT-5 (2024) confirmed superiority over semaglutide 2.4mg in head-to-head comparison.
-
Type 2 Diabetes Glycemic Control (SURPASS Program): The SURPASS trials across multiple comparators (insulin glargine, semaglutide, dulaglutide) consistently demonstrated tirzepatide’s superiority in HbA1c reduction — establishing it as the most effective glucose-lowering agent in the GLP-1 class.
-
Sleep Apnea Research: The SURMOUNT-OSA trial (2024) demonstrated tirzepatide significantly reduces obstructive sleep apnea severity — an entirely novel indication that opens a new research direction for GLP-1/GIP dual agonism.
-
Adipose Tissue & Lipolysis: GIP receptor activation in adipocytes promotes lipolysis (fat breakdown) — a mechanism absent in single-receptor GLP-1 agonists. Preclinical and clinical data show tirzepatide produces greater reductions in visceral and ectopic fat than semaglutide.
-
NASH / Liver Fat Research: Tirzepatide demonstrates significant hepatic fat reduction in NASH models. Phase III SURMOUNT-NASH data shows liver fibrosis improvement — positioning it alongside semaglutide as a top research candidate for liver disease.
-
Cardiovascular Research (SURMOUNT-MMO): The ongoing cardiovascular outcomes trial examines tirzepatide’s effect on MACE in obese patients — with interim data suggesting favorable cardiovascular risk reduction, potentially rivaling semaglutide’s SELECT trial findings.
-
Bone & Musculoskeletal Research: GIP receptors are expressed in osteoblasts and skeletal muscle. Preclinical research is examining tirzepatide’s potential role in bone density maintenance and lean mass preservation — a unique dual-agonist research angle not available with semaglutide.
-
Neurological & Addiction Research: Both GLP-1 and GIP receptors are expressed in reward-relevant brain regions. Emerging preclinical data is examining tirzepatide’s effects on addiction pathways, neuroinflammation, and cognitive function — extending the research scope established by semaglutide’s neural data.
Research Reference
Tirzepatide Research Dosage Reference — Preclinical & Clinical Data Only
The following summarizes dosage ranges from published preclinical and clinical research. For reference only. Not a recommendation for human use.
| Research Protocol | Reported Dose | Route | Duration (Studies) |
|---|---|---|---|
| Glycemic / Metabolic (rodent) | 0.3–10 nmol/kg | SC injection | Acute – 28 days |
| T2D Glycemic (SURPASS trials) | 5–15 mg/week | SC injection | 40–52 weeks |
| Obesity / Body Weight (SURMOUNT) | 5–15 mg/week | SC injection | 72–88 weeks |
| vs Semaglutide (SURMOUNT-5) | 10–15 mg/week | SC injection | 72 weeks |
| Sleep Apnea (SURMOUNT-OSA) | 10–15 mg/week | SC injection | 52 weeks |
| NASH / Liver Fat | 5–15 mg/week (Phase III) | SC injection | 52 weeks |
Data sourced from peer-reviewed preclinical and clinical literature. Tirzepatide requires a prescription for human therapeutic use. Research compound use must comply with all applicable regulations.
Frequently Asked Questions
Tirzepatide For Sale — Buyer FAQs
Reviews
There are no reviews yet.